Mazyar Malakouti, MD

Navigating Emotional Burden in IBD

In the final episode, “Navigating Emotional Burdenin IBD,” the panelists explored the emotional and psychological burden associated with inflammatory bowel disease (IBD), including the impact of anxiety, depression, fatigue, and fear of symptom flares on daily life. The patient panelist shares personal experiences navigating uncertainty, bowel urgency, dietary restrictions, and concerns about traveling or leaving home while living with Crohn’s disease. The panel also highlights how uncontrolled symptoms can significantly affect confidence, independence, social engagement, and overall quality of life.

Throughout the discussion, expert faculty emphasize the importance of normalizing conversations around mental health in patients with IBD and encouraging patients to openly discuss symptoms, emotional challenges, and treatment concerns with their healthcare providers. The panel reviews how early diagnosis and treatment with advanced therapies may help improve symptom control, reduce disease burden, and support better long-term physical and emotional outcomes. Expert faculty also discuss the importance of proactive communication, symptom tracking, and ongoing monitoring to help guide individualized treatment decisions and optimize disease management.

In addition, the patient panelist reflects on how biologic therapy and consistent communication with the healthcare team helped restore confidence in daily activities, including travel, diet, sleep, and exercise. The panel also highlights the importance of maintaining healthy routines, staying active, and advocating for oneself throughout the disease journey. The discussion concludes with key takeaways centered on patient empowerment, early intervention, and the ability of modern IBD therapies to help patients achieve remission and regain a more normal quality of life. Thank you for watching this peer exchange series on inflammatory bowl disease from the patient’s perspective. Please subscribe to our newsletter for information on upcoming video series.

Videos

Unpack embarrassing gut symptoms, learn why “IBS” may mask Crohn’s, and see how honest talks, tests, and biologics lead to remission.

Open Communication Between Patients and Providers in IBD

In “Open Communication Between Patients and Providers in IBD,” our panel explores the importance of symptom recognition, open patient-provider communication, and early evaluation in inflammatory bowel disease (IBD). The patient panelist reflects on the challenges associated with discussing gastrointestinal symptoms, including urgency, abdominal pain, bowel accidents, and dietary triggers, while emphasizing how important it is for patients to feel comfortable communicating honestly with their healthcare providers. The panel also highlights how patients may normalize or dismiss symptoms over time, delaying evaluation and treatment for conditions such as Crohn’s disease and ulcerative colitis.

Throughout the discussion, expert faculty examine how clinicians distinguish IBD from other gastrointestinal conditions such as irritable bowel syndrome (IBS) and explain why persistent symptoms should be thoroughly evaluated through diagnostic testing and specialist referral when appropriate. The panel discusses how symptom awareness, stool studies, colonoscopy findings, and patient-reported experiences all contribute to identifying active inflammatory disease and guiding treatment decisions.

In addition, the conversation reinforces the value of early treatment intervention and patient engagement throughout the disease journey. The patient panelist shares perspectives on adapting to life with biologic therapy, including experiences with injections, travel, medication adherence, and achieving remission. Expert faculty and the patient panelist emphasize that patients should not feel embarrassed discussing symptoms or asking questions about treatment, monitoring, and side effects. The panel concludes by highlighting how early diagnosis, open communication, and advanced therapies can improve disease control and help patients achieve a better quality of life while living with IBD.

Our next episode, “Navigating Emotional Burdenin IBD,” highlights how patients address the emotional burden of inflammatory bowel disease, including anxiety, depression, fatigue, and fear surrounding symptoms and flares. The panel also discusses how early treatment, biologic therapies, and open communication with healthcare providers can support remission and improve overall quality of life in patients with IBD.

Embarrassing gut issues deserve answers: testing can uncover IBS or Crohn’s, and early biologic treatment helps achieve remission.

Improving Quality of Life with Biologic Therapy in IBD

In this episode, “Improving Quality of Life with Biologic Therapy in IBD,” the panelists explore the long-term patient experience with biologic therapy and the impact of treatment on remission, confidence, and quality of life in inflammatory bowel disease (IBD). The patient panelist reflects on adapting to life with Crohn’s disease, discussing how biologic therapy became part of a manageable routine and helped restore a sense of normalcy and peace of mind. The panel also highlights the importance of treatment adherence, ongoing monitoring, and maintaining open communication with the healthcare team throughout the disease journey.

Throughout the discussion, expert faculty address common patient fears surrounding biologic therapies, including concerns related to side effects and long-term safety. The panel reviews the importance of patient education and shared decision-making, emphasizing that the risks associated with uncontrolled IBD may outweigh the potential risks of advanced therapies. Expert faculty also discuss how clinicians counsel patients on common adverse events, monitoring expectations, and when patients should contact their care team regarding new or worsening symptoms.

In addition, the conversation reinforces the importance of early diagnosis and early treatment intervention to reduce complications and improve long-term outcomes in IBD. The patient panelist shares how achieving remission improved the ability to travel, participate in family activities, and regain confidence in daily life without constant concern about symptoms or disease flares. The panel concludes by emphasizing that modern IBD therapies can help patients achieve meaningful symptom control, remission, and an improved quality of life through proactive, individualized care.

The next episode in this series, “Open Communication Between Patients and Providers in IBD,” features the panelists discussing the importance of early symptom recognition, honest communication with healthcare providers, and timely evaluation for inflammatory bowel disease. The panel will also highlight how biologic therapies, patient engagement, and early intervention can improve remission and quality of life in patients living with IBD.

Learn why controlling IBD matters more than feared side effects, and how biologics, monitoring, and whole-person care restore normal life.

Addressing Safety Concerns with Biologic Therapies in IBD

This episode, titled “Addressing Safety Concerns with Biologic Therapies in IBD,” features panelists discussing the role of safety considerations, patient education, and long-term disease management in inflammatory bowel disease (IBD). Expert faculty explore common patient concerns surrounding biologic and advanced therapies, including fear of side effects and uncertainty regarding long-term treatment. The panel emphasizes the importance of balancing these concerns with the risks associated with uncontrolled inflammation and ongoing disease activity, including complications and extraintestinal manifestations such as joint pain and dermatologic conditions.

Throughout the discussion, expert faculty review how treatment selection is individualized based on the patient’s overall clinical picture, including comorbidities and symptoms beyond the gastrointestinal tract. The panel also highlights how therapies such as IL-23 inhibitors and JAK inhibitors may provide benefits across multiple inflammatory conditions. Using a patient case discussion, the patient panelist shares experiences with adverse dermatologic effects during prior therapy and describes how coordination between gastroenterology and dermatology specialists helped guide treatment decisions and optimize care.

In addition, the conversation reinforces the importance of ongoing monitoring and preventive care in patients receiving biologic therapies, including laboratory monitoring, vaccinations, dermatologic evaluations, and routine health maintenance. Expert faculty discuss how patient reassurance, education, and close follow-up can help reduce fear surrounding advanced therapies and improve confidence in treatment decisions. The panel concludes by emphasizing that the goals of modern IBD management extend beyond symptom control and focus on helping patients achieve a more normal quality of life through individualized, proactive care.

In the next episode, “Improving Quality of Life with Biologic Therapy in IBD,” panelists will discuss how biologic therapies can help patients achieve remission, regain confidence in daily activities, and improve long-term quality of life in IBD. The panel will also highlight the importance of treatment adherence, patient education, and early intervention in optimizing outcomes for patients living with inflammatory bowel disease.

Learn how IBD patients get fast access to Tremfya, navigate insurance, and stay in remission with ongoing tests and doctor teamwork.

Mazyar Malakouti, MD

Articles